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Hyaluronidase has been gaining interest because it reduces tissue edema and fibrosis. Although rare, hyaluronidase 
has been shown to cause allergic reactions. A few cases of allergic reactions following hyaluronidase administration 
have been reported. Most of the described patients presented allergic reactions after peribulbar anesthesia for eye 
surgery. In this report, we describe three patients who experienced with allergic reactions to hyaluronidase following 
pain management. Two of the patients had a history of uneventful injection with hyaluronidase. All patients were 
afebrile and blood tests results were normal. Intradermal skin tests were positive. These clinical findings were helpful 
in establishing the differential diagnosis of infection. Although allergic reaction to hyaluronidase is rare and mostly 
benign, this must be considered before treating patients. (Korean J Anesthesiol 2011; 60: 57-59)
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    Hyaluronidase is an enzyme with spreading activity [1] that 
hydrolyzes hyaluronic acid which is a key element of connective 
tissue [2]. Thus, the spread of local anesthetics can be improved 
by hyaluronidase. Clinically, it reduces tissue swelling due to 
trauma and also reduces fibrosis to fibrin deposits and chronic 
inflammation [3]. Therefore, it has been gaining interest for use 
in chronic pain management.
    Although hyaluronidase has been used worldwide, only a 
few allergic reactions to hyaluronidase have been reported. 
Most of the described patients showed allergic reactions after 
peribulbar anesthesia for eye surgery [2,4-7]. The authors 
describe three cases of allergic reactions after hyaluronidase 
administration in pain management. 
Case Reports
Case 1
    A 68-year-old woman with lower back pain due to spinal 
stenosis underwent caudal block with 0.2% lidocaine and 
1,500 IU of hyaluronidase (H-lase
Ⓡ; Kuhnil, Korea). She had 
previously received uneventful caudal block with same mixture 58 www.ekja.org
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of drugs. After injection, she complained of itching sensation, 
and a generalized maculo-papular rash developed. However, 
no hypotension was found. Because she had several uneventful 
injections of local anesthetics, hyaluronidase was suspected. 
She was treated with dexamethasone and pheniramine 
intravenously. After one hour, symptoms diminished. 
Subseqeuntly, she has not shown any allergic response to drugs 
excluding hyaluronidase during pain management.
Case 2
    A 35-year-old woman suffering from medial elbow pain was 
injected with 1% lidocaine and 1,500 IU of hyaluronidase into 
the common flexor tendon. Her previous history of exposure to 
hyaluronidase was unknown. Twelve hours later, the injection 
site was swollen along with mild pain. These symptoms 
continued for one day. The patient was afebrile. Besides the 
complete blood cell count, erythrocyte sedimentation rate and 
C-reactive protein level were normal. She was suspected to be 
allergic to hyaluronidase, and the subsequent intradermal skin 
allergy test result was positive. Consequently, hyaluronidase 
was eliminated from the injection. Since she was treated 
with only 1% lidocaine, there have been no allergic reactions 
identified. 
Case 3
    A 55-year-old woman with medial knee pain received an 
injection of 1% lidocaine and 1,500 IU of hyaluronidase into her 
anserinus bursa. She also had a history of uneventful injection 
with the same mixture of drugs several weeks beforehand. 
The following day, she showed a severely swollen medial 
knee that lasted for three days. She was not pyrexic and blood 
test results were normal. Skin allergy test revealed reactivity 
to hyaluronidase. She received several injections without 
hyaluronidase and, consequently, no allergic reactions were 
observed. 
Discussion
    Although hyaluronidase has been extensively used in 
anesthesia and pain medicine, there are very few reported cases 
of hypersensitivity reaction. Kempeneers et al. [4] were the 
first to report on the etiology of hyaluronidase reaction in five 
cases. Allergic reactions to hyaluronidase are rare (incidence is 
1/2,000) [2], and most of these occur in peribulbar anesthesia 
during ophthalmic surgery [8]. To our knowledge, however, this 
is the first report of allergic reaction to hyaluronidase during 
pain management. 
    The clinical manifestation of allergic reaction to hyaluronidase 
after peribulbar anesthesia appears to be similar in most 
cases [5]. Symptoms are usually mild without optic nerve 
compromise; however, a number of cases with reversible visual 
deterioration have occurred. 
    In general, allergic reactions to hyaluronidase result in 
localized responses in the injection area without generalized 
symptoms. However, more generalized reactions can occur 
according to the route of administration [8]. Szépfalusi et al. [1] 
reported that five of sixteen pediatric cancer patients showed 
immediate generalized allergic reactions after hyaluronidase-
chemotherapeutic agent mixture was intravenously injected. In 
this report, only our first patient presented with an immediate, 
generalized symptom after injection. As the aforementioned 
cases suggest, the reaction can also occur as a result of an 
incidental intravenous injection during caudal block. Since 
capillary permeability is massively increased by hyaluronidase 
[6], extra caution should be taken. However, further evaluation 
is needed to determine whether or not intravenous injection 
causes generalized allergic reactions.
    Two patients had a history of uneventful hyaluronidase 
injection. Due to previous exposure, sensitization has taken 
place and allergic reaction to additional hyaluronidase 
injection was identified. On the other hand, there was a case 
of allergic response that appeared at the first administration 
of hyaluronidase [4]; thus, more than two types of allergic 
mechanisms may be involved. Although the exact types of 
hypersensitivity are unclear, many researchers have suggested 
that Type I and Type IV hypersensitivity are associated [2,4,7]. 
In this report, an immediate onset of symptom could represent 
a Type I (IgE-mediated) anaphylactic reaction. Further, reaction 
delayed for 24 hours could be a Type IV (T-cell- mediated) 
anaphylactic reaction. 
    The complete blood analysis, including white blood cell 
count, erythrocyte sedimentation rate, and C-reactive protein, 
could be useful to make a differential diagnosis of infection. 
Because all our patients had normal blood test results and 
they were afebrile and were systemically well, we easily ruled 
out infection. Skin allergy tests, such as intradermal and skin 
prick test, are the most specific and common methods for 
determining the drug responsible for Type I (IgE-mediated) 
anaphylactic reactions [4,5]. Furthermore, confirmation of 
delayed cell-mediated allergic reaction can be performed by 
lymphocytic transformation test [4]. In this report, intradermal 
skin test was performed with hyaluronidase (15 IU/ml) and a 
positive result was recorded for a persistent wheal of greater 
than 0.8 cm [9].
    The addition of hyaluronidase to local anesthetics has been 
a controversial issue [2]. Some authors have insisted that there 
is insufficient evidence for using hyaluronidase with local 
anesthetics for chronic back pain management [10], while 59 www.ekja.org
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another study failed to show the advantage of hyaluronidase 
injection for local anesthesia [11]. When only these 
considerations are taken into account, due to potential allergic 
reactions, the use of hyaluronidase with local anesthetics in pain 
management might be reconsidered. However, interestingly, 
many other authors have insisted that hyaluronidase with 
local anesthetics reduces the anesthetic volume needed 
and improves the efficacy of local anesthesia [12-14]. Since 
symptoms in most cases, including this report, are benign, 
infrequent and not prolonged, risk of complication might not 
be significant. Delaere et al. [2] carefully recommended the use 
of hyaluronidase in spite of potential allergic responses. 
    In conclusion, although symptoms are usually benign and 
improve within a few days, an allergic reaction to hyaluronidase 
can occur in pain practice. Therefore, extra caution has to be 
urged to avoid hyaluronidase injection into patients with this 
allergy. Additionally, allergic reaction should be considered 
in the differential diagnosis of patients who demonstrate 
characteristic clinical symptoms and signs after hyaluronidase 
administration.
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